Abstract:
This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
Abstract:
Verwendung oligomerer Carbodiimide enthaltend mindestens eine heterocyclische Endgruppe, als Stabilisatoren für Polymere. Wobei die oligomeren Carbodiimide Verbindungen der allgemeinen Formel (I) sein können, wobei A 1 , A 2 unabhängig voneinander, gleich oder verschieden, Kohlenwasserstoffgruppen mit 2 bis 20 Kohlenstoffatomen, B 1 , B 2 unabhängig voneinander, gleich oder verschieden, Heterocyclen, C 1 -C 30 -Alkohole, Poyletherole, Polyesterole, Amine, Polyetheramine, Polyesteramine, Thioalkohole, Polyetherthiole, Polyesterthiole, R 1 , R 2 unabhängig voneinander, gleich oder verschieden, (A), n ganze Zahl im Bereich von 2 bis 100, sind und wobei A 1 , A 2 , B 1 und B 2 jeweils an beliebiger Position durch C 1 -C 20 -Alkyl, C 2 -C 20 -Alkenyl, C 2 -C 20 -Alkinyl, C 1 -C 20 -Alkoxy, Carbonyl-Sauerstoff (=O) oder Halogen substituiert sein können, unter der Maßgabe, das mindestens ein Substituent B 1 oder B 2 eine heterocyclische Endgruppe ist. Weiterhin Verfahren zur Stabilisierung von Polymeren gegen Hydrolyse durch oligomeren Carbodiimide.
Abstract:
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using phannaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Abstract:
The invention concerns 2-aminithiazoline derivatives of formula (I) wherein: either R1 is a hydrogen atom or an alkyl radical and R2 is an alkyl, -alk-NH2, -CH-R3, -CH2-S-R4 or phenyl radical substituted by a nitro or NH-C(=NH)CH3 radical; or R1 is an alkyl radical and R2 is a hydrogen atom; R3 is a cycloalkyl (3-6C), pyridyl, pyridyl N-oxide, thienyl, thiazolyl, imidazolyl, pyrazinyl, triazolyl, phenyl or phenyl radical substituted by a nitro, hydroxy or carboxy radical; R4 represents a pyridyl or pyridyl N-oxide radical; alk represents an alkylene radical or their pharmaceutically acceptable salts excluding some known compounds, and the use of said derivatives as inducible NO-synthase inhibitors.
Abstract:
Compounds of formula (I) wherein R1 is C1-C4-alkyl or cyclopropyl; R2 is C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkinyl; or C1-C6-alkyl substituted by 1 to 5 fluorine atoms; R3 is C1-C6-alkyl, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkinyl, C2-C6-alkinyloxy, C1-C6-alkoxycarbonyl, CN, or aryl, heteroaryl, heterocyclyl, aryloxy, heteroaryloxy or heterocyclyloxy, whereby the above-mentioned groups may be substituted by identical of different substituents, R5 signifies hydrogen or methyl; R6 and R7 are C1-C4-alkyl; have microbicidal, insecticidal and acaricidal activity and may be used for the control of pests and plant-pathogenic fungi in agriculture, horticulture and in the field of hygiene.
Abstract:
Compounds of formula (I) which inhibit leukocyte adhesion mediated by interaction of the alpha 4 beta 1 integrin (VLA-4) with its counterreceptor VCAM-1, and their use for the treatment of inflammatory and autoimmune diseases.
Abstract:
Novel aminoalkylphenols, intermediates and processes for the preparation thereof, and methods of relieving memory dysfunction utilizing the aminoalkylphenols or compositions thereof are disclosed.
Abstract:
Described are compounds for targeting proteases, e.g. serine proteases and their use in the diagnostic methods and methods for treatment of respiratory diseases such as cystic fibrosis. The compounds have the structure [H]-[B]-[A]; wherein [H] is a hydrophilic group, [B] is a subsite recognition group and [A] is a binding group; wherein A has the formula: -C(0)-CH 2 -NR 1 -COOR 2 and wherein [B] has the structure :(i)-[CO-CH 2 - NR 3 ]m-, or (ii)-[AA1-AA2]- or (iii) -(AA1-C0-CH 2 NR 3 )- or (iv) -(CO-CH 2 -NR 3 - AA1)- or (v) -(C0-CH 2 -NR 4 -AA1-AA3)-.
Abstract:
: The invention discloses a novel process for highly chemoselective reactions of substituted anilines without any detectable reaction at aromatic amino group. The invention also relates to a novel process for preparation of neostigmine methylsulphate via chemoselective reaction of 3-amionphenol and aryl dimethylcarbamates.
Abstract:
The present invention provides a process for the preparation of a 11 C of 18 F- labelled carbamate comprising reacting a primary or secondary amine or an anion thereof with carbon dioxide and a compound of formula RX or R 1 X, wherein X represents a leaving group; R represents an alkyl or alkylene containing group; R 1 represents an alkyl or alkylene containing group which group comprises a 18 F-label; and said group R and/or the carbon dixoide has a 11 C-labelled carbon atom.